These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24796317)

  • 1. Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies.
    Fabiani E; Falconi G; Fianchi L; Guidi F; Bellesi S; Voso MT; Leone G; D'Alò F
    Exp Hematol; 2014 Sep; 42(9):731-3. PubMed ID: 24796317
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 3. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.
    Lee Tokar L; Crotty G; O'Keeffe D; Langabeer SE
    Blood Cells Mol Dis; 2021 Sep; 90():102593. PubMed ID: 34217938
    [No Abstract]   [Full Text] [Related]  

  • 4. MicroRNAs in myeloid malignancies.
    Gordon JE; Wong JJ; Rasko JE
    Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence conservation of RAG-1 and RAG-2 genes in hematologic malignancies.
    Mulero MC; Estivill C; Corral J; Sierra J; Baiget M; Nomdedéu JF
    Leukemia; 2002 Aug; 16(8):1571. PubMed ID: 12145704
    [No Abstract]   [Full Text] [Related]  

  • 6. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.
    Nangalia J; Nice FL; Wedge DC; Godfrey AL; Grinfeld J; Thakker C; Massie CE; Baxter J; Sewell D; Silber Y; Campbell PJ; Green AR
    Haematologica; 2015 Nov; 100(11):e438-42. PubMed ID: 26250577
    [No Abstract]   [Full Text] [Related]  

  • 7. Notch one up to stroma: endothelial notch prevents inflammation and myeloproliferation.
    Khalaj M; Park CY
    Cell Stem Cell; 2014 Jul; 15(1):1-2. PubMed ID: 24996160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.
    MacGrogan D; Kalakonda N; Alvarez S; Scandura JM; Boccuni P; Johansson B; Nimer SD
    Genes Chromosomes Cancer; 2004 Nov; 41(3):203-13. PubMed ID: 15334543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZBTB7A links tumor metabolism to myeloid differentiation.
    Redondo Monte E; Kerbs P; Greif PA
    Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and functional significance of osteocalcin splicing in disease progression of hematological malignancies.
    Wihlidal P; Varga F; Pfeilstöcker M; Karlic H
    Leuk Res; 2006 Oct; 30(10):1241-8. PubMed ID: 16387359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational determinants of epigenetic instablity in myeloid malignancies.
    Jankowska AM; Szpurka H
    Semin Oncol; 2012 Feb; 39(1):80-96. PubMed ID: 22289495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.
    Couronné L; Scourzic L; Pilati C; Della Valle V; Duffourd Y; Solary E; Vainchenker W; Merlio JP; Beylot-Barry M; Damm F; Stern MH; Gaulard P; Lamant L; Delabesse E; Merle-Beral H; Nguyen-Khac F; Fontenay M; Tilly H; Bastard C; Zucman-Rossi J; Bernard OA; Mercher T
    Haematologica; 2013 Nov; 98(11):1748-52. PubMed ID: 23872306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Notch disruption on myeloid development.
    Francis OL; Chaudhry KK; Lamprecht T; Klco JM
    Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212
    [No Abstract]   [Full Text] [Related]  

  • 14. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
    Anastasi J
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
    Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
    Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.
    Bench AJ; Erber WN; Scott MA
    Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.
    Meggendorfer M; Jeromin S; Haferlach C; Kern W; Haferlach T
    Haematologica; 2018 May; 103(5):e192-e195. PubMed ID: 29700173
    [No Abstract]   [Full Text] [Related]  

  • 19. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
    Berger R
    Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
    [No Abstract]   [Full Text] [Related]  

  • 20. Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells.
    Abbonante V; Gruppi C; Catarsi P; Avanzini MA; Tira ME; Barosi G; Rosti V; Balduini A
    Br J Haematol; 2016 Jan; 172(1):140-4. PubMed ID: 25940987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.